NCT02559622 - Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Psoriasis

Interventions

DRUG

Secukinumab

300 mg secukinumab

OTHER

Placebo

Placebo followed by 300 mg secukinumab

OTHER

Placebo

Placebo followed by 150 mg secukinumab

DRUG

Secukinumab

150 mg secukinumab

Trial Locations (23)

10789

Novartis Investigative Site, Berlin

13187

Novartis Investigative Site, Berlin

20354

Novartis Investigative Site, Hamburg

21682

Novartis Investigative Site, Stade

23538

Novartis Investigative Site, Lübeck

33647

Novartis Investigative Site, Bielefeld

44791

Novartis Investigative Site, Bochum

45147

Novartis Investigative Site, Essen

47166

Novartis Investigative Site, Duisburg

48149

Novartis Investigative Site, Münster

53105

Novartis Investigative Site, Bonn

55131

Novartis Investigative Site, Mainz

60590

Novartis Investigative Site, Frankfurt

64283

Novartis Investigative Site, Darmstadt

66421

Novartis Investigative Site, Homburg

69120

Novartis Investigative Site, Heidelberg

79104

Novartis Investigative Site, Freiburg im Breisgau

81675

Novartis Investigative Site, München

86179

Novartis Investigative Site, Augsburg

89081

Novartis Investigative Site, Ulm

89129

Novartis Investigative Site, Langenau

01307

Novartis Investigative Site, Dresden

07548

Novartis Investigative Site, Gera